Myostatin Inhibitor Market Set to Scale from $140.00 Million to $1.65 Billion by 2035

Myostatin Inhibitor Market

The Myostatin Inhibitor Market was valued at $140.00 Million in 2025 and is projected to reach $1.65 Billion by 2035, growing at a CAGR of 28.0 percent over 2026 to 2035, according to Strategic Revenue Insights. Muscle preservation for patients on obesity drugs is the main driver, adding 5.0 percentage points to growth, because weight loss therapies remove lean mass along with fat.

Click here for free sample PDF: https://www.strategicrevenueinsights.com/industry/myostatin-inhibitor-market

Myostatin Inhibitor Market Key Takeaways

  • The market grows 11.8 times, from $140.00 million in 2025 to $1.65 billion in 2035, passing $481.04 million in 2030.
  • Sarcopenia is the largest indication at 34 percent of 2025 revenue; obesity-related muscle preservation grows fastest at 36.2 percent.
  • Monoclonal antibodies lead drug classes with 46 percent; propeptide-targeting antibodies grow fastest at 32.5 percent.
  • Hospital pharmacies dispense 52 percent of value, while specialty pharmacies grow fastest at 31.0 percent.
  • North America holds 55 percent of revenue and Asia Pacific grows fastest at 32.3 percent.

What Is Driving Growth

Four drivers lift the market. Obesity drug muscle preservation adds 5.0 points, as payers and doctors want to limit lean mass loss during GLP-1 treatment. Add-on therapies for spinal muscular atrophy add 3.5 points, aging populations with few approved sarcopenia drugs add 3.0 points, and orphan drug incentives that speed neuromuscular launches add 2.0 points. Mixed clinical results from earlier programs and reimbursement uncertainty for chronic injections are the main restraints, taking away 3.0 and 2.0 points.

Segments, Regions and Key Players

Today’s sale is an antibody given under hospital supervision: hospitals hold 49 percent of end user revenue. Growth points elsewhere. Homecare settings grow fastest at 32.0 percent as subcutaneous formulations and autoinjectors move chronic therapy into the home, and specialty clinics are expected to pass hospitals in value by 2035. Propeptide-targeting antibodies, which block the activation of latent myostatin, are expected to match conventional antibodies in value by 2035.

North America leads with 55 percent and Europe holds 22 percent. Key players include Scholar Rock, Regeneron, Roche, Eli Lilly, Biohaven, Novartis and Keros Therapeutics.

Frequently Asked Questions

How big is the myostatin inhibitor market?

It is worth $140.00 million in 2025 and is forecast to reach $1.65 billion by 2035, a 28.0 percent CAGR.

Which indication grows fastest?

Obesity-related muscle preservation, at 36.2 percent a year, reaching $399.59 million by 2035.

Which region leads the market?

North America holds 55 percent of 2025 revenue, while Asia Pacific grows fastest at 32.3 percent.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd headquartered in London, provides syndicated market research reports, consulting and strategic insights. Contact: sales@strategicrevenueinsights.com | www.strategicrevenueinsights.com